DYSTROPHY, LANDOUZY-DEJERINE

Clinical trials for DYSTROPHY, LANDOUZY-DEJERINE explained in plain language.

Never miss a new study

Get alerted when new DYSTROPHY, LANDOUZY-DEJERINE trials appear

Sign up with your email to follow new studies for DYSTROPHY, LANDOUZY-DEJERINE, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Completed 1

New hope for FSHD: experimental drug AOC 1020 tested in humans

Disease control Completed

This study tested an experimental drug called AOC 1020 in 90 adults with facioscapulohumeral muscular dystrophy (FSHD), a rare genetic disease that causes progressive muscle weakness. The main goals were to check the drug's safety and how the body processes it. Participants recei…

Matched conditions: DYSTROPHY, LANDOUZY-DEJERINE

Phase: PHASE1, PHASE2 • Sponsor: Avidity Biosciences, Inc. • Aim: Disease control

Last updated May 01, 2026 16:00 UTC

DYSTROPHY, LANDOUZY-DEJERINE

Get alerted when new DYSTROPHY, LANDOUZY-DEJERINE trials appear

New hope for FSHD: experimental drug AOC 1020 tested in humans